See highlights from GHTC's 2022 Innovating for Impact Awards

Search the GHTC website

Texas

Texas

Global health R&D delivers for Texas

US government investment in global health R&D has delivered

Amount
$201.6 million
to Texas research institutions
Jobs
3,100+ new jobs
for Texas
Texas

Neglected diseases in Texas

Chikungunya cases
Chikungunya cases
201
Dengue cases
Dengue cases
248
HIV diagnoses
HIV diagnoses
39274
Malaria cases
Malaria cases
676
Tuberculosis cases
Tuberculosis cases
11998
West Nile cases
West Nile cases
3370
Zika cases
Zika cases
364
Texas's top USG-funded global health R&D institutions

Texas's top USG-funded global health R&D institutions

University of Texas Medical Branch at Galveston
$36.9 million
Texas A&M University (including Engineering Experiment Station)
$32.6 million
University of Texas at Dallas (including University of Texas Southwestern Medical Center at Dallas)
$25.5 million
University of Texas at San Antonio (including University of Texas Health Science Center San Antonio)
$18.9 million
Texas Biomedical Research Institute
$15 million
Southwest Foundation for Biomedical Research
$11.5 million
University of Texas at Austin
$10 million
Texas Tech University
$8.4 million
Baylor College of Medicine
$7.1 million
University of Texas at Houston (including University of Texas Health Science Center at Houston)
$5.1 million
Rice University
$4 million
Texas Agrilife Research
$4 million
PharmaReview Corporation
$3.5 million
University of Texas Health Center at Tyler
$2.7 million
Methodist Hospital Research Institute
$1.9 million
University of Houston
$1.3 million
Southwest Research Institute
$1.2 million
University of Texas M.D. Anderson Cancer Center
$466 thousand
Baylor Research Institute
$436 thousand
Southern Methodist University
$242 thousand
Seralogix
$149 thousand
University of North Texas Health Science Center
$99 thousand
Texas Children's Hospital (including the Baylor International Pediatric AIDS Initiative and the Botswana-Baylor Children's Clinical Center of Excellence)
$84 thousand
Texas industry in global health R&D

Texas industry in global health R&D

AI Biosciences
Location(s): College Station
AM Biotechnologies
Location(s): Houston
Bayer
Location(s): Pasadena
Beckman Coulter
Location(s): Irving
Celgene
Location(s): Dallas
Charles River Laboratories
Location(s): Houston
J-LABS
Location(s): Houston
Luminex
Location(s): Austin
Novartis
Location(s): Forth Worth, Houston
Omm Scientific
Location(s): Dallas
Paratus Diagnostics
Location(s): San Marcos
PharmaReview Corporation
Location(s): Houston
Westat
Location(s): Austin, Houston, San Antonio

Texas's top areas of global health R&D by USG funding

9.6%
HIV/AIDS
9.4%
Malaria
29.9%
Tuberculosis
11.5%
Diarrheal diseases
4.1%
Ebola/viral hemorrhagic fevers
2.8%
Salmonella infections
29.4%
Neglected tropical diseases
Buruli ulcer
Dengue
Helminths
Kinetoplastids
Trachoma
3.3%
Other
Bacterial pneumonia & meningitis
Global health R&D at work in Texas

University of Texas Medical Branch at Galveston is using a computer-based discovery approach to identify potential new drugs for dengue and similar diseases for which there are currently no effective treatments. Almost half of the world’s population is at risk for dengue, a mosquito-borne infection related to hepatitis C, West Nile, and yellow fever. New treatments could have a huge impact on improving health worldwide.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Cornelius Brudi